Clinical trials: Hematology
Anemia
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
This study will assess the comfort of subcutaneous injections of NeoRecormon and darbepoetin alfa (Aranesp) in patients with renal anemia.
- Trial name
- NCT00377481
- Testing
- darbepoetin alfa, epoetin beta [NeoRecormon]
- Where
- 8 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
The investigators postulate that Pevonedistat will be effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) when combined with a standard backbone ALL chemotherapy regimen.
- Trial name
- NCT03349281
- Testing
- Pevonedistat, Vincristine, Dexamethasone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Julio Barredo, MD
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439123
- Testing
- Capivasertib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Examination of Trends in Multiple Myeloma Trial Patient Experiences
Historically, participation in clinical trials has been highly skewed towards specific demographic groups. However, research identifying which trial attributes impact participation, in either positive or negative ways, is…
- Trial name
- NCT05860179
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Ischemic Stroke, Stroke in the Young
Observational Dutch Young Symptomatic StrokE studY - nEXT
BACKGROUND: Worldwide, 2 million patients aged 18-50 years suffer an ischemic stroke each year with an increasing trend over the past decade due to yet unknown reasons.
- Conditions
- Ischemic Stroke, Stroke in the Young, Cardiovascular Diseases, Cerebrovascular Disorders
- Trial name
- ODYSSEY-nEXT (NCT05853796)
- Where
- 6 sites in Netherlands
- Volunteers
- 280 people
- Sponsor
- Radboud University Medical Center
Pseudotumor Cerebri, Cystinosis
The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study
This study will examine whether the tendency to have thrombosis, or the formation of blood clots inside blood vessels, has a role in the development of pseudotumor cerebri (PTC).
- Trial name
- NCT00071903
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Multiple Myeloma
Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
This study evaluates the efficacy of the addiction of Cyclophosphamide to Revlimid-low dose dexamethasone (Rd) in relapsed/refractory Multiple Myeloma patients, who experienced a biochemical progression, without CRAB, during Rd…
- Trial name
- NCT02206503
- Testing
- Cyclophosphamide, Lenalidomide, Dexamethasone
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Fondazione EMN Italy Onlus
Relapse Leukemia
Outcome Following Truncation of Asparaginase
This study aimed to investigate the outcome of patients who had their asparaginase treatment truncated in the NOPHO ALL2008 protocol.
- Trial name
- NCT03987542
- Where
- Denmark
- Volunteers
- 1,401 people
- Sponsor
- Birgitte Klug Albertsen
Hematologic Malignancy
Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies
This research study is studying the removal of a subset of white blood cells (called alpha/beta T cells) from the donor product using a cell separation device before the product is transplanted into the participant.
- Trial name
- NCT03717480
- Testing
- ClinicMACs
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Dana-Farber Cancer Institute
Iron-deficiency, Iron Deficiency Anemia
Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability
Phytic acid is a known inhibitor of iron bioavailability, although long term studies have suggested possibly exaggerated findings compared to single meal studies, pointing to phytic acid adaptation over time.
- Trial name
- NCT03030703
- Testing
- phytic acid
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Kansas State University
Paroxysmal Nocturnal Hemoglobinuria
A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)
A safety and immunogenicity study in long-term treatment of Eculizumab (JSC "GENERIUM", Russian Federation) in patients with paroxysmal nocturnal hemoglobinuria, who have been involved earlier in the clinical trials of Eculizumab…
- Trial name
- NAP (NCT04679103)
- Testing
- Eculizumab (JSC GENERIUM, Russia)
- Where
- 9 sites in Russia
- Volunteers
- 50 people
- Sponsor
- AO GENERIUM
Thalassemia Major, Covid19
Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases
In Italy there are about 5000 patients with dependent transfusion thalassemia (source Italian Thalassemia and Hemoglobinopathies - SITE) and a smaller number, currently not definable, of patients with sickle cell anemia in…
- Trial name
- ThalaCoV (NCT04526405)
- Testing
- SARS-CoV-2 S1/S2 IgG
- Where
- Italy
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Milano Bicocca
Acute Myeloid Leukemia
Expanded Access to ABBV-787
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-787 prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Trial name
- NCT06439966
- Testing
- ABBV-787
- Sponsor
- AbbVie
Multiple Myeloma, Newly Diagnosed
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
This study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT.
- Trial name
- ElLen (NCT06918002)
- Testing
- Elranatamab, Lenalidomide (Revlimid®), Daratumumab SC (Darzalex)
- Where
- 69 sites in Belgium, France
- Volunteers
- 824 people
- Sponsor
- Intergroupe Francophone du Myelome
Acute Myeloid Leukemia
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
Phase 3 study to evaluate the efficacy and safety of dociparstat sodium in adults with newly diagnosed untreated acute myeloid leukemia (AML) with adverse or intermediate genetic risk.
- Trial name
- AML (NCT04571645)
- Testing
- Dociparstat, Control
- Where
- 14 sites in United States
- Volunteers
- 9 people
- Sponsor
- Jazz Pharmaceuticals
Eosinophilic Esophagitis
The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Pilot)
The purpose of the study is to evaluate of the relationships between fractionated exhaled nitric oxide, disease activity, and symptom severity in patients with eosinophilic esophagitis compared to those without eosinophilic…
- Trial name
- NCT03812575
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The University of Texas Health Science Center, Houston
COVID-19
Study on the Recovery of Pulmonary Function, Chest CT, Airway Microbiota, Hematologic, and Immune & Inflammatory Conditions in COVID-19 Rehabilitation Patients
The intent of this study was to examine the health status of individuals who had been confirmed with COVID-19 in the year after their recovery.
- Trial name
- NCT04456101
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
MPN-RC 118 AVID200 in Myelofibrosis
Increased levels of TGF-β1 were detected in serum, plasma and BM and positively correlated with both grade of BMF and extent of leukemic cell infiltration in the marrow.
- Conditions
- Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post ET MF
- Trial name
- NCT03895112
- Testing
- AVID200
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- John Mascarenhas
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
This study was designed as a prospective, multicenter, open-label, randomized controlled trial. Eligible participants were patients aged 15-65 years with high risk or relapsed/refractory acute myeloid leukemia (AML), acute…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
- Trial name
- NCT07575412
- Testing
- SHR2554/AZA + Overlapped mBUCY, mBUCY conditioning Regimen Group
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability and to establish the maximum tolerated dose of JNJ-26481585 combined with VELCADE and dexamethasone.
- Trial name
- NCT01464112
- Testing
- JNJ-2641585 / VELCADE / Dexamethasone
- Where
- 3 sites in France
- Volunteers
- 18 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.